TrialLancet (London, England)2021

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.

Ly-Mee Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.